Global Recombinant Human Follicle Stimulating Hormone Injection 麻豆原创 Research Report 2024

Publication ID:

PB508240115

Publication Date:

August 6, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global Recombinant Human Follicle Stimulating Hormone Injection market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Recombinant Human Follicle Stimulating Hormone Injection is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Recombinant Human Follicle Stimulating Hormone Injection is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Recombinant Human Follicle Stimulating Hormone Injection include Merck, LG Chem, Ferring Pharmaceuticals, MSD, IBSA Institut Biochimique, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Recombinant Human Follicle Stimulating Hormone Injection, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Human Follicle Stimulating Hormone Injection.
The Recombinant Human Follicle Stimulating Hormone Injection market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Recombinant Human Follicle Stimulating Hormone Injection market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Human Follicle Stimulating Hormone Injection manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Merck
LG Chem
Ferring Pharmaceuticals
MSD
IBSA Institut Biochimique
Segment by Type
66渭g (900IU)
33渭g (450IU)
11渭g (150IU)
Segment by Application
Hospital
Clinic
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Recombinant Human Follicle Stimulating Hormone Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Recombinant Human Follicle Stimulating Hormone Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.鈥�

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Recombinant Human Follicle Stimulating Hormone Injection 麻豆原创 Overview
1.1 Product Definition
1.2 Recombinant Human Follicle Stimulating Hormone Injection by Type
1.2.1 Global Recombinant Human Follicle Stimulating Hormone Injection 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 66渭g (900IU)
1.2.3 33渭g (450IU)
1.2.4 11渭g (150IU)
1.3 Recombinant Human Follicle Stimulating Hormone Injection by Application
1.3.1 Global Recombinant Human Follicle Stimulating Hormone Injection 麻豆原创 Value by Application (2024-2030)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Recombinant Human Follicle Stimulating Hormone Injection 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Recombinant Human Follicle Stimulating Hormone Injection Revenue 2019-2030
1.4.2 Global Recombinant Human Follicle Stimulating Hormone Injection Sales 2019-2030
1.4.3 Global Recombinant Human Follicle Stimulating Hormone Injection 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Recombinant Human Follicle Stimulating Hormone Injection 麻豆原创 Competition by Manufacturers
2.1 Global Recombinant Human Follicle Stimulating Hormone Injection Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global Recombinant Human Follicle Stimulating Hormone Injection Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global Recombinant Human Follicle Stimulating Hormone Injection Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Recombinant Human Follicle Stimulating Hormone Injection, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Recombinant Human Follicle Stimulating Hormone Injection, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Recombinant Human Follicle Stimulating Hormone Injection, Product Type & Application
2.7 Global Key Manufacturers of Recombinant Human Follicle Stimulating Hormone Injection, Date of Enter into This Industry
2.8 Global Recombinant Human Follicle Stimulating Hormone Injection 麻豆原创 Competitive Situation and Trends
2.8.1 Global Recombinant Human Follicle Stimulating Hormone Injection 麻豆原创 Concentration Rate
2.8.2 The Global 5 and 10 Largest Recombinant Human Follicle Stimulating Hormone Injection Players 麻豆原创 Share by Revenue
2.8.3 Global Recombinant Human Follicle Stimulating Hormone Injection 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Recombinant Human Follicle Stimulating Hormone Injection 麻豆原创 Scenario by Region
3.1 Global Recombinant Human Follicle Stimulating Hormone Injection 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Recombinant Human Follicle Stimulating Hormone Injection Sales by Region: 2019-2030
3.2.1 Global Recombinant Human Follicle Stimulating Hormone Injection Sales by Region: 2019-2024
3.2.2 Global Recombinant Human Follicle Stimulating Hormone Injection Sales by Region: 2025-2030
3.3 Global Recombinant Human Follicle Stimulating Hormone Injection Revenue by Region: 2019-2030
3.3.1 Global Recombinant Human Follicle Stimulating Hormone Injection Revenue by Region: 2019-2024
3.3.2 Global Recombinant Human Follicle Stimulating Hormone Injection Revenue by Region: 2025-2030
3.4 North America Recombinant Human Follicle Stimulating Hormone Injection 麻豆原创 Facts & Figures by Country
3.4.1 North America Recombinant Human Follicle Stimulating Hormone Injection 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Recombinant Human Follicle Stimulating Hormone Injection Sales by Country (2019-2030)
3.4.3 North America Recombinant Human Follicle Stimulating Hormone Injection Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Recombinant Human Follicle Stimulating Hormone Injection 麻豆原创 Facts & Figures by Country
3.5.1 Europe Recombinant Human Follicle Stimulating Hormone Injection 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Recombinant Human Follicle Stimulating Hormone Injection Sales by Country (2019-2030)
3.5.3 Europe Recombinant Human Follicle Stimulating Hormone Injection Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Recombinant Human Follicle Stimulating Hormone Injection 麻豆原创 Facts & Figures by Region
3.6.1 Asia Pacific Recombinant Human Follicle Stimulating Hormone Injection 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Recombinant Human Follicle Stimulating Hormone Injection Sales by Region (2019-2030)
3.6.3 Asia Pacific Recombinant Human Follicle Stimulating Hormone Injection Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Recombinant Human Follicle Stimulating Hormone Injection 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Recombinant Human Follicle Stimulating Hormone Injection 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Recombinant Human Follicle Stimulating Hormone Injection Sales by Country (2019-2030)
3.7.3 Latin America Recombinant Human Follicle Stimulating Hormone Injection Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Recombinant Human Follicle Stimulating Hormone Injection 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Recombinant Human Follicle Stimulating Hormone Injection 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Recombinant Human Follicle Stimulating Hormone Injection Sales by Country (2019-2030)
3.8.3 Middle East and Africa Recombinant Human Follicle Stimulating Hormone Injection Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Recombinant Human Follicle Stimulating Hormone Injection Sales by Type (2019-2030)
4.1.1 Global Recombinant Human Follicle Stimulating Hormone Injection Sales by Type (2019-2024)
4.1.2 Global Recombinant Human Follicle Stimulating Hormone Injection Sales by Type (2025-2030)
4.1.3 Global Recombinant Human Follicle Stimulating Hormone Injection Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Recombinant Human Follicle Stimulating Hormone Injection Revenue by Type (2019-2030)
4.2.1 Global Recombinant Human Follicle Stimulating Hormone Injection Revenue by Type (2019-2024)
4.2.2 Global Recombinant Human Follicle Stimulating Hormone Injection Revenue by Type (2025-2030)
4.2.3 Global Recombinant Human Follicle Stimulating Hormone Injection Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Recombinant Human Follicle Stimulating Hormone Injection Price by Type (2019-2030)
5 Segment by Application
5.1 Global Recombinant Human Follicle Stimulating Hormone Injection Sales by Application (2019-2030)
5.1.1 Global Recombinant Human Follicle Stimulating Hormone Injection Sales by Application (2019-2024)
5.1.2 Global Recombinant Human Follicle Stimulating Hormone Injection Sales by Application (2025-2030)
5.1.3 Global Recombinant Human Follicle Stimulating Hormone Injection Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Recombinant Human Follicle Stimulating Hormone Injection Revenue by Application (2019-2030)
5.2.1 Global Recombinant Human Follicle Stimulating Hormone Injection Revenue by Application (2019-2024)
5.2.2 Global Recombinant Human Follicle Stimulating Hormone Injection Revenue by Application (2025-2030)
5.2.3 Global Recombinant Human Follicle Stimulating Hormone Injection Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Recombinant Human Follicle Stimulating Hormone Injection Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Company Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Recombinant Human Follicle Stimulating Hormone Injection Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Merck Recombinant Human Follicle Stimulating Hormone Injection Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 LG Chem
6.2.1 LG Chem Company Information
6.2.2 LG Chem Description and Business Overview
6.2.3 LG Chem Recombinant Human Follicle Stimulating Hormone Injection Sales, Revenue and Gross Margin (2019-2024)
6.2.4 LG Chem Recombinant Human Follicle Stimulating Hormone Injection Product Portfolio
6.2.5 LG Chem Recent Developments/Updates
6.3 Ferring Pharmaceuticals
6.3.1 Ferring Pharmaceuticals Company Information
6.3.2 Ferring Pharmaceuticals Description and Business Overview
6.3.3 Ferring Pharmaceuticals Recombinant Human Follicle Stimulating Hormone Injection Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Ferring Pharmaceuticals Recombinant Human Follicle Stimulating Hormone Injection Product Portfolio
6.3.5 Ferring Pharmaceuticals Recent Developments/Updates
6.4 MSD
6.4.1 MSD Company Information
6.4.2 MSD Description and Business Overview
6.4.3 MSD Recombinant Human Follicle Stimulating Hormone Injection Sales, Revenue and Gross Margin (2019-2024)
6.4.4 MSD Recombinant Human Follicle Stimulating Hormone Injection Product Portfolio
6.4.5 MSD Recent Developments/Updates
6.5 IBSA Institut Biochimique
6.5.1 IBSA Institut Biochimique Company Information
6.5.2 IBSA Institut Biochimique Description and Business Overview
6.5.3 IBSA Institut Biochimique Recombinant Human Follicle Stimulating Hormone Injection Sales, Revenue and Gross Margin (2019-2024)
6.5.4 IBSA Institut Biochimique Recombinant Human Follicle Stimulating Hormone Injection Product Portfolio
6.5.5 IBSA Institut Biochimique Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Recombinant Human Follicle Stimulating Hormone Injection Industry Chain Analysis
7.2 Recombinant Human Follicle Stimulating Hormone Injection Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Recombinant Human Follicle Stimulating Hormone Injection Production Mode & Process
7.4 Recombinant Human Follicle Stimulating Hormone Injection Sales and 麻豆原创ing
7.4.1 Recombinant Human Follicle Stimulating Hormone Injection Sales Channels
7.4.2 Recombinant Human Follicle Stimulating Hormone Injection Distributors
7.5 Recombinant Human Follicle Stimulating Hormone Injection Customers
8 Recombinant Human Follicle Stimulating Hormone Injection 麻豆原创 Dynamics
8.1 Recombinant Human Follicle Stimulating Hormone Injection Industry Trends
8.2 Recombinant Human Follicle Stimulating Hormone Injection 麻豆原创 Drivers
8.3 Recombinant Human Follicle Stimulating Hormone Injection 麻豆原创 Challenges
8.4 Recombinant Human Follicle Stimulating Hormone Injection 麻豆原创 Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Merck
LG Chem
Ferring Pharmaceuticals
MSD
IBSA Institut Biochimique

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.